Michael Kaleko

4.7k total citations
76 papers, 3.9k citations indexed

About

Michael Kaleko is a scholar working on Molecular Biology, Genetics and Infectious Diseases. According to data from OpenAlex, Michael Kaleko has authored 76 papers receiving a total of 3.9k indexed citations (citations by other indexed papers that have themselves been cited), including 47 papers in Molecular Biology, 37 papers in Genetics and 19 papers in Infectious Diseases. Recurrent topics in Michael Kaleko's work include Virus-based gene therapy research (37 papers), Hemophilia Treatment and Research (14 papers) and Clostridium difficile and Clostridium perfringens research (12 papers). Michael Kaleko is often cited by papers focused on Virus-based gene therapy research (37 papers), Hemophilia Treatment and Research (14 papers) and Clostridium difficile and Clostridium perfringens research (12 papers). Michael Kaleko collaborates with scholars based in United States, Switzerland and South Africa. Michael Kaleko's co-authors include A. Dusty Miller, Sheila Connelly, Alan McClelland, William J. Rutter, Theodore A Smith, Dawn B. Kayda, Michele G. Mehaffey, Neeraja Idamakanti, J. Victor Garcia and Bruce C. Trapnell and has published in prestigious journals such as Cell, Journal of Biological Chemistry and Nature Genetics.

In The Last Decade

Michael Kaleko

75 papers receiving 3.8k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Michael Kaleko United States	37	2.6k	2.1k	1.1k	525	520	76	3.9k
Lars Rogge France	33	1.2k 0.5×	560 0.3×	844 0.8×	160 0.3×	168 0.3×	77	4.5k
Jacques F.A.P. Miller Australia	30	1.1k 0.4×	728 0.3×	1.4k 1.2×	137 0.3×	113 0.2×	61	6.8k
J A Bluestone United States	18	522 0.2×	1.2k 0.6×	1.6k 1.5×	95 0.2×	221 0.4×	29	6.4k
Gunnar V. Alm Sweden	49	872 0.3×	593 0.3×	1.6k 1.5×	203 0.4×	136 0.3×	121	8.0k
Barry J. Sugarman United States	18	1.4k 0.5×	665 0.3×	676 0.6×	134 0.3×	69 0.1×	31	2.7k
Philip J. Lucas United States	23	713 0.3×	353 0.2×	1.1k 1.0×	122 0.2×	93 0.2×	32	5.6k
Tsuyoshi Uchida Japan	25	1.5k 0.6×	721 0.3×	370 0.3×	138 0.3×	43 0.1×	79	2.8k
Georg H. Fey Germany	35	1.3k 0.5×	290 0.1×	1.1k 1.0×	205 0.4×	72 0.1×	71	3.1k
Petter Höglund Sweden	38	570 0.2×	737 0.3×	1.1k 1.0×	69 0.1×	132 0.3×	119	5.6k
Sophie M. Lehar United States	18	1.3k 0.5×	227 0.1×	644 0.6×	113 0.2×	213 0.4×	22	3.9k

Countries citing papers authored by Michael Kaleko

Since Specialization

Citations

This map shows the geographic impact of Michael Kaleko's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Michael Kaleko with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Michael Kaleko more than expected).

Fields of papers citing papers by Michael Kaleko

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Michael Kaleko. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Michael Kaleko. The network helps show where Michael Kaleko may publish in the future.

Co-authorship network of co-authors of Michael Kaleko

This figure shows the co-authorship network connecting the top 25 collaborators of Michael Kaleko. A scholar is included among the top collaborators of Michael Kaleko based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Michael Kaleko. Michael Kaleko is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Pazo-Cid, Roberto, T. Macarulla Mercadé, Berta Laquente, et al.. (2025). 2216MO VIRAGE trial: Randomized phase IIb, open-label, study of nab-paclitaxel and gemcitabine with/without intravenous VCN-01 in patients with metastatic pancreatic cancer (mPDAC). Annals of Oncology. 36. S1146–S1147.

García‐Carbonero, Rocio, Roberto Pazo-Cid, Teresa Macarulla, et al.. (2024). VIRAGE: A phase IIb, open-label, randomized study of nab-paclitaxel and gemcitabine plus/minus VCN-01 in patients with metastatic pancreatic cancer.. Journal of Clinical Oncology. 42(16_suppl). TPS4210–TPS4210. 1 indexed citations

Connelly, Sheila, Brian Fanelli, Nur A. Hasan, Rita R. Colwell, & Michael Kaleko. (2019). Low dose oral beta-lactamase protects the gut microbiome from oral beta-lactam-mediated damage in dogs. AIMS Public Health. 6(4). 477–487. 6 indexed citations

Connelly, Sheila, Christian Furlan-Freguia, Brian Fanelli, et al.. (2018). 620. Oral β-Lactamase Therapies Prevent Microbiome Damage and Attenuate Antibiotic Resistance From IV and Oral Antibiotics in Large Animal Models of Antibiotic-Mediated Gut Dysbiosis. Open Forum Infectious Diseases. 5(suppl_1). S226–S226. 2 indexed citations

Connelly, Sheila, Poorani Subramanian, Nur A. Hasan, Rita R. Colwell, & Michael Kaleko. (2018). Distinct consequences of amoxicillin and ertapenem exposure in the porcine gut microbiome. Anaerobe. 53. 82–93. 31 indexed citations

Kaleko, Michael, J. Andrew Bristol, Todd B. Parsley, et al.. (2016). Development of SYN-004, an oral beta-lactamase treatment to protect the gut microbiome from antibiotic-mediated damage and prevent Clostridium difficile infection. Anaerobe. 41. 58–67. 55 indexed citations

Oshima, Yuji, Tye Deering, Sachiko M. Oshima, et al.. (2004). Angiopoietin‐2 enhances retinal vessel sensitivity to vascular endothelial growth factor. Journal of Cellular Physiology. 199(3). 412–417. 77 indexed citations

Oshima, Yuji, Kyoichi Takahashi, Sachiko M. Oshima, et al.. (2004). Intraocular gutless adenoviral‐vectored VEGF stimulates anterior segment but not retinal neovascularization. Journal of Cellular Physiology. 199(3). 399–411. 14 indexed citations

Burroughs, Kevin D., Dawn B. Kayda, Kiran Sakhuja, et al.. (2004). Potentiation of oncolytic adenoviral vector efficacy with gutless vectors encoding GMCSF or TRAIL. Cancer Gene Therapy. 11(2). 92–102. 8 indexed citations

10.

Reddy, P. Seshidhar, Shanthi Ganesh, Terrence W. Brann, et al.. (2003). Development of adenovirus serotype 35 as a gene transfer vector. Virology. 311(2). 384–393. 108 indexed citations

11.

Zhang, Jingli, et al.. (2002). Mapping of the Bovine Immunodeficiency Virus Packaging Signal and RRE and Incorporation into a Minimal Gene Transfer Vector. Virology. 304(1). 10–23. 9 indexed citations

12.

Reddy, P. Seshidhar, Kiran Sakhuja, Shanthi Ganesh, et al.. (2002). Sustained Human Factor VIII Expression in Hemophilia A Mice Following Systemic Delivery of a Gutless Adenoviral Vector. Molecular Therapy. 5(1). 63–73. 89 indexed citations

13.

Bristol, J. Andrew, Pamela S. Shirley, Neeraja Idamakanti, Michael Kaleko, & Sheila Connelly. (2000). In Vivo Dose Threshold Effect of Adenovirus-Mediated Factor VIII Gene Therapy in Hemophiliac Mice. Molecular Therapy. 2(3). 223–232. 37 indexed citations

14.

Shirley, Pamela S., J. Andrews, Dawn B. Kayda, et al.. (1999). In Vivo Evaluation of an Adenoviral Vector Encoding Canine Factor VIII: High-Level, Sustained Expression in Hemophiliac Mice. Human Gene Therapy. 10(11). 1791–1802. 36 indexed citations

15.

Persons, Derek A., Michele G. Mehaffey, Michael Kaleko, Arthur W. Nienhuis, & Elio F. Vanin. (1998). An Improved Method for Generating Retroviral Producer Clones for Vectors Lacking a Selectable Marker Gene. Blood Cells Molecules and Diseases. 24(2). 167–182. 74 indexed citations

16.

Connelly, Sheila, et al.. (1996). High-Level Tissue-Specific Expression of Functional Human Factor VIII in Mice. Human Gene Therapy. 7(2). 183–195. 57 indexed citations

17.

Smith, Theodore A, Michele G. Mehaffey, Dawn B. Kayda, et al.. (1993). Adenovirus mediated expression of therapeutic plasma levels of human factor IX in mice. Nature Genetics. 5(4). 397–402. 295 indexed citations

18.

Quinn, LeBris S., et al.. (1993). Ligand‐dependent inhibition of myoblast differentiation by overexpression of the type‐1 insulin‐like growth factor receptor. Journal of Cellular Physiology. 156(3). 453–461. 19 indexed citations

19.

Kaleko, Michael, et al.. (1992). Transformation mediated by the human HER-2 gene independent of the epidermal growth factor receptor.. PubMed. 7(9). 1859–66. 138 indexed citations

20.

Osborne, William, Randy A. Hock, Michael Kaleko, & A. Dusty Miller. (1990). Long-Term Expression of Human Adenosine Deaminase in Mice after Transplantation of Bone Marrow Infected with Amphotropic Retroviral Vectors. Human Gene Therapy. 1(1). 31–41. 54 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact